Background. The causal role of high-density lipoproteins (HDL) in coronary artery disease 3 (CAD) has been questioned. Our aim was to analyze whether genetically determined 4 quantitative and qualitative HDL characteristics were independently associated with CAD.
INTRODUCTION
The inverse association between high-density lipoprotein cholesterol (HDL-C) levels and the risk of coronary artery disease (CAD) has been reported in observational studies 1 . However, experimental and genetic studies question the causality of this association. On the one hand, drugs such as fibrates, niacin, and cholesteryl ester transfer protein inhibitors increase HDL-C levels but do not decrease CAD risk 2 . On the other hand, genetic predisposition to high HDL-C levels has not been linked to any decrease in the risk of cardiovascular events 3, 4 . Thus, researchers are looking beyond HDL-C levels to disentangle this apparent contradiction. Anti-atherogenic properties of HDL particles seem to be determined by the quality or function of the lipoprotein 5 . HDL particle size and number have been linked to cardiovascular risk 6 , and this association could be mediated through HDL functionality, which is predictive of cardiovascular risk 7 .
The interplay between HDL-C and triglyceride levels, as two of the faces of atherogenic dyslipidemia, may also play a relevant role in their relationship with CAD 8, 9 . Thus, further evidence of causal association between HDL characteristics and CAD risk would provide relevant data on the validity of these particles as therapeutic targets.
Mendelian Randomization (MR) studies have arisen as a powerful tool to ascertain the potential causality of the association between a biomarker and a disease 10 . These studies assess the association between the genetically determined lifelong values of a biomarker and the development of a clinical outcome. MR studies have already raised serious doubts on the causal role of quantitative HDL characteristics, such as HDL-C and apolipoprotein A-I (ApoA-I) levels, in CAD 3, 11 . However, to date, the association between qualitative HDL characteristics and CAD has not been tested using a MR approach. HDL mean diameter, the concentration of HDL particles of each size subtype, the distribution of cholesterol across the HDL size subtypes, and the presence of other lipids in HDL particles (such as triglycerides, highly present in large HDLs) are 2 some of these qualitative traits. Additionally, this evaluation must take into account the complexity of lipid metabolism and its potential genetic pleiotropic effects. HDL-C, lowdensity lipoprotein cholesterol (LDL-C), and triglyceride levels are highly interdependent and, therefore, the method used to test the association between HDL properties and CAD risk should take into account this inter-correlation 12 .
This study had two aims: 1) to assess the potential causal association of quantitative and qualitative HDL characteristics with CAD risk, using a two-sample MR approach;
and 2) to explore potential mechanisms explaining the observed associations.
METHODS

Study design and data sources
We designed a two-sample MR study using aggregated summary data 10 from three published meta-analyses of genome-wide association studies. The main analysis was based on data from Kettunen et al 13 We centered our analysis on the genetic variants associated with: 1) the main lipid profile traits in serum (HDL-C, LDL-C, and triglyceride levels); 2) other measurements of HDL quantity (ApoA-I levels); 3) HDL mean diameter; 4) the quantities of cholesterol transported in small, medium-sized, large and very large HDLs; 5) the quantity of other lipid species in HDL particles (triglycerides transported in very large HDLs); and 6) the levels of HDL particles according to the previous HDL size subtypes. Both the Kettunen et al and the METSIM studies measured HDL qualitative characteristics by the same nuclear magnetic resonance spectroscopy technique 16 .
Assessment of genetic variants linked to lipoprotein characteristics and CAD risk adjusted for other lipoprotein traits: Multi-Trait-based Conditional & Joint analyses
To identify the genetic variants associated with each lipoprotein characteristic that were also linked to CAD considering the potential pleiotropy among lipid profile traits, we used the Multi-trait-based Conditional & Joint analysis 17 in both the main and the validation stage. This method enables the estimation of the magnitude of the association of each genetic variant with each lipoprotein characteristic and with CAD, independently from the other genetically determined lipoprotein traits (adjusted effect sizes). For example, if we considered HDL-C as "main variable" and LDL-C and triglyceride levels as "covariates", we would obtain the betas and standard errors of the associations of genetic variants with (1) HDL-C (using the Kettunen and METSIM raw summary data) and (2) CAD (using the CARDIoGRAMplusC4D raw summary results), adjusted for the association of these same genetic variants with LDL-C and triglyceride concentrations. For this purpose, we defined six multivariate models a priori. Model 1 included HDL-C, LDL-C and triglyceride levels. Further models included the elements in Model 1 as covariates and the following parameters as main variables: ApoA-I levels (Model 2); HDL mean diameter (Model 3); the cholesterol content in each HDL size subtype (small, medium-sized, large, and very large HDL particles; Model 4); the levels of HDL particles of each size subtype (Model 5); and the triglyceride content in very large HDLs (Model 6). In model 4 and 5, we required for the presence of at least two of the HDL subtypes (small, medium-sized, large, and very large) traits to build the model.
The genetic correlation between traits was estimated by linkage disequilibrium score regressions using all genetic variants.
Mendelian randomization analyses
Based on the adjusted gene variant effects and their standard errors computed as previously described, we performed the MR analysis using the Generalized Summarydata-based Mendelian Randomization method 18 . The genetic variants to be considered were selected with the following criteria: 1) strong association with the lipid traits of interest (p-value<5·10 -8 ); 2) not in linkage disequilibrium (R 2 <0.01, using the 1000 Genome project data -http://www.1000genomes.org/phase-3-structural-variantdataset-as reference 19 ); and 3) a minor allele frequency ≥ 0.05.
As an additional approach to exclude potential pleiotropy, we also removed the variants with a significant result in the HEIDI-outlier test (p-value<0.01). Finally, we explored and confirmed the exclusion of potential pleiotropic effects using Egger regressions 20 .
Statistical significance of our results was corrected for multiple comparisons (p-value=0.05/number of traits). A description of complementary sensitivity analyses using other MR analyses methods such as the median-based and inverse variance weighted, using the Global Lipid Genetic Consortium dataset 21 and post-hoc statistical power estimations 22 is available in Supplemental Materials.
RESULTS
Mendelian randomization results
Selected genetic variants
We identified genetic variants significantly associated with 13 lipoprotein characteristics We observed high inverse genetic correlations (correlation coefficient≤-0.50) between triglyceride and HDL-C levels. Conversely, we observed very high direct genetic correlations (correlation coefficient≥0.70) between the cholesterol content in each HDL size subpopulation and HDL-C concentrations, between HDL mean diameter and the level of very large HDL particles, and between ApoA-I and the level of very large HDL particles and their cholesterol content (Supplemental Figure 1) .
Main analysis
We defined as statistically significant those associations with a p-value<3.85·10 -3 (0.05/13). We observed a direct association between CAD risk and genetically determined levels of LDL-C (β=0. 26 2D, and 2E) . The genetically determined levels of all subtypes of HDL particles showed an inverse trend towards an association with CAD risk, but only that between very large HDLs and CAD was statistically significant (β=-0.22 [-0.32; -0.12], p-value=7.12·10 -6 ) (Figure 1) . Finally, the genetically determined levels of triglycerides in very large HDLs were directly related to CAD risk (β=0.14 [0.040; 0.25], p-value=6.84·10 -3 ) (Figures 1 and 2F) . Effect sizes of all the associations are available in Supplemental Table 1 .
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Genetic variants linked to both HDL qualitative traits and CAD risk were located within LIPC, the APOE/C1/C4/C2 cluster, PCIF1, TTC39B, and APOB (Supplemental Excel File 1).
Validation analysis
In the validation analysis (Figure 1) , we confirmed the direct association between the (Figure 1 and Supplemental   Figure 2 ). We could not assess the associations between the levels of HDL particles and CAD due to the lack of genetic variants associated with at least two of these HDL traits in the METSIM study. The effect sizes of all the associations of interest are available in Supplemental Table 2 .
Sensitivity analysis
Egger regression intercept estimates supported the absence of pleiotropic effects.
Results of the median-based and inverse variance weighted methods confirmed the direction and significance of the main analyses (Supplemental Table 3 ).
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Associations between genetically determined HDL-C, LDL-C and triglyceride levels and CAD risk identified in our main analysis were similar to those obtained from the Global Lipid Genetic Consortium (Supplemental Table 4 ).
Post-hoc statistical power estimation
Power estimation for the main analyses ranged from 2.4% to 96.9% (Supplemental Table 5 ).
DISCUSSION
Our findings suggest a potential causal relationship between qualitative HDL characteristics and CAD risk, even though HDL-C and ApoA-I levels were not associated with CAD. In particular, genetically determined mean HDL size, the distribution of cholesterol across HDL size subpopulations, and the triglyceride content in HDL particles were related to CAD risk.
The relationship between HDL and cardiovascular risk is controversial 4 . Recent studies suggest that HDL functions and quality characteristics, rather than HDL-C concentration, are the main determinants of HDL anti-atherogenic properties 5 . Our data are consistent with previous evidence, and reflect that HDL-C and ApoA-I levels in the bloodstream are not causally related to CAD 3, 11 . However, we observed a decrease in CAD risk when HDL-C was mainly transported in smaller HDLs, but an increase in CAD risk when HDL-C was carried by larger HDL particles (in both main and validation analyses, there is a gradient towards greater CAD risk as more cholesterol is transported in larger HDLs). Our results contribute to explaining why HDL-C levels are not causally associated with cardiovascular risk, as the protective effect of cholesterol content in medium-sized HDLs may be counterbalanced by the adverse effect of 8 cholesterol levels in larger particles. These results are consistent with previous experimental evidence, and could contribute to explain the therapeutic failure of the pharmacological agents known to increase HDL-C levels. Niacin or cholesteryl ester transfer protein inhibitors are effective in increasing HDL-C concentrations but not in reducing CAD risk; this paradox could be explained by a promotion of the accumulation of cholesterol content in large HDLs 2 . In gemfibrozil-treated patients, changes in HDL-C levels accounted for a small proportion of the CAD risk reduction (<10%), whereas the increase in small HDLs was much more predictive of this risk reduction 23 . Our results also concur with genetic studies analyzing variants in the SR-B1 gene, showing that individuals with loss-of-function variants have higher HDL-C concentrations, mainly in very large particles, but also higher CAD risk 24 .
However, there is still controversy in the relationship between HDL size subtypes and cardiovascular risk: some authors advocate for small HDLs as indicators of lower CAD risk 25 while others suggest they are associated with increased CAD risk 26 procedures to measure HDL size (nuclear magnetic resonance spectroscopy, electrophoresis, etc.) differed between the published studies, and there is low concordance between these techniques 28 . Third, the statistical models used did not consider all the same confounding factors and did not always include as covariates the levels of HDL-C or other lipid profile parameters related to these lipoproteins (e.g. triglyceride concentrations).
Triglyceride and HDL-C levels may be two sides of the same coin, and this relationship may contribute to explaining why HDL-C is not causally related to CAD while triglycerides are. Hypertriglyceridemic states (generally due to high levels of very-low density lipoprotein concentrations in plasma) are linked to an increased activity of the cholesteryl ester transfer protein, an enzyme that exchanges triglycerides in very-low density lipoproteins for cholesterol in HDLs, resulting in an enrichment of HDLs in triglycerides 8 . Aged HDL particles may also become increasingly richer in triglycerides because this exchange is an essential process by which HDLs get rid of the cholesterol they have collected from peripheral cells and transfer it back to the liver 29 . In any case, triglyceride-rich HDLs have been shown to present their ApoA-I in an unstable conformation 30 , which may be related to lower HDL function (lower cholesterol efflux capacity) and a greater disintegration of the HDL structure (lower HDL-C levels) 8 . Our results confirm that triglyceride-rich HDLs are causally related to higher CAD risk independently from the circulating levels of triglycerides and HDL-C. In addition, this mechanism also verifies the hypothesis that high triglycerides (in circulation and in HDL particles) are essential mediators of high cardiovascular risk and suggests that low HDL-C levels in these states may be a secondary consequence of this lipid disruption.
Both observational and experimental studies have more consistently found an inverse relationship between the number of HDL particles and cardiovascular risk, compared to HDL-C levels 7 . Similarly, we observed that the concentrations of HDL particles of all sizes were inversely related to CAD risk, although only the genetically determined levels of very large HDLs were significantly associated with it in the main analysis.
Unfortunately, we could not validate these results due to the lack of valid genetic variants in the METSIM study.
Our results are mechanistically plausible and highlight novel potential therapeutic targets in cardiovascular disease, since genetic variants individually associated with HDL qualitative traits and CAD in our data were located within five HDL-related genes or gene clusters. First, LIPC encodes for hepatic lipase C, an enzyme that hydrolyzes triglycerides in circulating lipoproteins, including HDL particles 29 . Hydrolysis of HDL triglycerides by this enzyme generates small/medium-sized, triglyceride-depleted particles, considered to be more stable and functional than very large, triglyceride-rich HDLs 31 . Since triglyceride-rich HDLs were also causally linked to CAD in our data, this potential mechanism would contribute to explaining a decrease in cardiovascular risk.
Second, the APOE/C1/C4/C2 cluster encodes apolipoproteins E, C-I, C-II, and C-IV and has been classically associated with blood lipid levels 32 . Among these proteins, two are particularly related to HDL metabolism: apolipoprotein E (ApoE) and apolipoprotein C-I (ApoC-I). ApoE is a pivotal mediator in reverse cholesterol transport which is one of the most essential HDL function 33 . ApoC-I is involved in the modulation of two key enzymes of HDL cholesterol metabolism: the activation of lecithincholesterol acyltransferase and the inhibition of cholesteryl ester transfer protein 34, 35 .
The third HDL-related locus encodes the PDX1 C-Terminal Inhibiting Factor 1 and is located next to the PLTP gene, which expresses the phospholipid transfer protein, an enzyme involved in HDL remodeling/stabilization and the generation of lipid-free/lipidpoor small HDLs 29 . PCIF1-related gene variants have been shown to modulate phospholipid transfer protein function in other studies 36 . Fourth, TTC39B encodes the tetratricopeptide repeat domain protein 39B, whose genetic variants had already been associated with HDL-C levels and CAD in previous works 32, 37 . Fifth, APOB encodes for apolipoprotein B, the essential apolipoprotein in chylomicrons, LDLs, and very-low density lipoproteins. Although its relationship with HDL biology may seem distant, gene variants located in this gene have been surprisingly associated with HDL cholesterol levels in four large genome-wide association studies 32, [38] [39] [40] .
Our study has several methodological strengths. First, our results are based in MR, a useful approach to explore the causality of the association between biomarkers and specific diseases. Second, we included two independent MR analyses to validate the results initially observed. Finally, the validity of the genetic variants for HDL-C, LDL-C and triglyceride levels initially generated was confirmed, supporting the validity of these datasets for the analysis of other genetic variants. However, our study also has limitations. First, in order to use a MR approach, we had to make some assumptions 10 , among which stands out the absence of pleiotropy. In our case, most of the genetic variants used as instruments were associated with more than one lipid trait. To solve this problem, we used a novel approach (Multi-trait based Conditional & Joint analysis-Generalized Summary data-based Mendelian randomization methodology) to control for the confounding effects related to the close relationship between lipoprotein characteristics and to minimize pleiotropy 17 . Second, the interpretation of multivariable MR is challenging, especially when the covariate-biomarker lies on the causal pathway from the main-biomarker to disease, or when the covariate-biomarker measures the same entity as the main-biomarker 41 . Third, the statistical power of our analyses was limited for some of the traits of interest. Finally, in the validation analysis we could not generate GIVs for some of the lipoprotein traits.
CONCLUSIONS
Our study indicates that several genetically and life-long qualitative HDL characteristics were related to CAD risk. Although HDL-C and ApoA-I levels were not causally linked to CAD, our results support a potential causality between higher mean HDL diameter, greater cholesterol levels in very large HDLs, and triglyceride-rich HDL particles and higher CAD risk, and between cholesterol levels in medium-sized HDLs and lower CAD risk. This relationship could be mediated by several HDL-related proteins (hepatic lipase; apolipoproteins E, C-I, and B; phospholipid transfer protein; and tetratricopeptide repeat domain protein 39B), which are suggested as potential therapeutic targets for further exploration in cardiovascular prevention. 
